Clinical trials
Other Solid Tumors clinical trials
Below are recruiting other solid tumors clinical trials, each written for real people, not researchers. We’re tracking 1,683 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05068583Recruiting
Testing liquid blood samples in children with certain cancers
This trial studies “liquid biopsies,” which are blood tests, to help learn about specific cancers in children. It may help doctors monitor cancer and guide treatment using less invasive tests.
Los Angeles, CaliforniaAges 6 months+ - NCT04762641RecruitingPhase 1
First-dose safety study of ABL503 for advanced cancers
This Phase 1 trial tests the safety and side effects of ABL503 and finds the best dose to study next. It is for people with advanced cancer that is growing despite prior treatment options.
Duarte, CaliforniaAges 18 years+ - NCT05718895RecruitingPhase 1
ATG-022 for advanced solid tumors that have stopped responding
This early-phase study tests ATG-022 in adults with advanced or metastatic solid cancers that have progressed on standard treatment, cannot use standard treatment, or have no standard option. It may help by targeting cancer cells differently, and participation includes close monitoring and likely a biopsy.
AdelaideAges 18 years+ - NCT05405595RecruitingPhase 1/Phase 2
Study drug with pembrolizumab for advanced solid tumors
This early-stage trial tests a new investigational drug (ADG126) combined with pembrolizumab in people with advanced or metastatic solid tumors. It aims to find a safe dose and see whether the combination can shrink tumors.
Scottsdale, ArizonaAges 18 years+ - NCT03772561RecruitingPhase 1
Testing AZD5363, olaparib, and durvalumab for advanced solid cancers
This Phase 1 trial tests a combination of three medicines to shrink or control advanced solid tumors that are progressing or no standard options exist. It mainly focuses on safety and early signs of how well the treatment works.
Singapore, SingaporeAges 21–99 - NCT04387916RecruitingPhase 1
Test drug KC1036 in people with advanced solid tumors
This Phase 1 trial studies how a new medicine (KC1036) works and how safe it is for people with advanced solid cancers that have grown despite standard treatments. It may help future patients by showing whether the drug can control cancer in difficult-to-treat cases.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT05547321RecruitingPhase 1
New cancer drug plus immunotherapy for advanced solid tumors
This early-phase trial studies OMTX705, given by itself or with an anti–PD-1 immune therapy, in people with advanced solid cancers that can’t be cured or that stopped responding to standard treatments. It aims to check safety and see whether the treatment can shrink tumors or control disease.
Boston, MassachusettsAges 18 years+ - NCT05263960RecruitingPhase 1/Phase 2
CM350 drug study for advanced solid tumors
This trial tests CM350 in people with advanced solid cancers that are hard to treat with standard options. It may help by finding a safe dose and whether the drug can work against these cancers.
Chengdu, SichuanAges 18–75 - NCT04093466RecruitingPhase 1
Testing a new pill for advanced solid tumors
This Phase 1 trial tests kanitinib (CX1003), a new cancer medicine, in people with advanced solid tumors that have come back or stopped responding to standard treatment. The goal is to find a safe dose and see early signs of tumor response.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06257680RecruitingPhase 1
ReT01 cell therapy for advanced solid tumors
This trial tests a new cell therapy called ReT01 for people with advanced solid tumors that have stopped responding to standard treatments. It uses your own immune cells from a tumor sample to fight the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT05701709RecruitingPhase 1
First-in-human test for a new drug in advanced solid cancers
This Phase 1 study tests SHR-A2102, a new cancer medicine, in adults with advanced solid tumors. It mainly looks at safety and how the body handles the drug, and it may help if standard treatments are not working or are not an option.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07141706RecruitingPhase 1
Testing DB-1317 in advanced solid tumors
This trial tests an investigational drug (DB-1317) that targets a protein called ADAM9, found on some solid tumors. It is for people with advanced cancers that have not responded to other treatments, and aims to see if the drug is safe and works.
Los Angeles, CaliforniaAges 18 years+ - NCT07128303RecruitingPhase 1
GS-5319 for adults with solid tumors lacking MTAP
This trial tests an investigational drug called GS-5319 in people with solid tumors that are missing a protein called MTAP. It is for those whose cancer has continued to grow after other treatments or who cannot have standard therapy.
Boston, MassachusettsAges 18 years+ - NCT06240546RecruitingPhase 1
Study of LPM6690176 for advanced solid tumors
This trial tests a new drug called LPM6690176 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects the body.
BeijingAges 18–75 - NCT06197139RecruitingPhase 1
Study of a new targeted radiation therapy for advanced solid tumors
This trial tests an investigational drug called [177Lu]Lu-XT117, which delivers a small dose of radiation directly to cancer cells that have a specific protein called FAP. It is for people with advanced solid tumors who have run out of standard treatment options or cannot tolerate them.
GuangzhouAges 18 years+ - NCT06038396RecruitingPhase 1/Phase 2
A study of RC118 plus toripalimab/RC148 for advanced stomach cancer
This trial tests a new drug combination (RC118 plus toripalimab/RC148) for people with advanced stomach or gastroesophageal junction cancer. It’s for those whose cancer has not responded to standard treatment and whose tumors have a specific protein called Claudin 18.2.
Fuzhou, FujianAges 18–75 - NCT07139067RecruitingPhase 1
YK1101 for advanced solid tumors
This trial tests a new cell therapy called YK1101 for people with advanced solid tumors that have not responded to standard treatment. It targets a specific protein (MAGE-A4) on cancer cells and requires a matching genetic type called HLA-A*11:01.
BeijingAges 18–75 - NCT06480552RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT06417554RecruitingPhase 1/Phase 2
Study of SHR-A2102 with or without other cancer drugs for advanced solid tumors
This trial tests a new drug, SHR-A2102, given alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapy or for those who have not yet received systemic treatment. The goal is to see if it can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06443489RecruitingPhase 1
SHR-4849 for advanced solid tumors
This trial tests a new drug called SHR-4849 for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective, and may offer a new option for those who have limited choices.
Jilin City, ChangchunAges 18–75 - NCT06413615RecruitingPhase 2
Study of a new targeted drug for advanced solid tumors with HER2
This study tests a new antibody-drug conjugate (FDA022-BB05) for people with advanced solid cancers—especially breast, endometrial, bladder, colorectal, or lung cancer—that have stopped responding to standard therapy. The drug targets HER2, a protein on some cancer cells, to try to shrink tumors or slow their growth.
ShanghaiAges 18–75 - NCT06882135RecruitingPhase 1
Testing an experimental drug for advanced solid tumors
This trial studies a new drug called HW071021 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can help shrink or control the cancer.
Guangzhou, GuangdongAges 18 years+ - NCT06187402RecruitingPhase 1/Phase 2
Study of LM-24C5 for advanced solid tumors
This trial tests a new drug called LM-24C5 for people with advanced solid tumors that have stopped responding to standard treatments or who can't tolerate them. It aims to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06825494RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Hefei, AnhuiAges 18 years+
Hear when a new Other Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for other solid tumors?
- Yes. Clin2 currently lists 1,683 recruiting other solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a other solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a other solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.